Moleculin Biotech is trading 15.6% down today at $0.86 as the stock extends a sharp multi-day slide amid investor focus on its cash runway and clinical trial developments.
- The move follows a significant decline from $2.19 to $1.02 in regular trading, with shares exhibiting extreme intraday volatility and heavy speculative activity.
- Broader risk-on market sentiment has failed to stem the selling pressure as traders weigh the company's financial sustainability.
- Market participants remain focused on the latest clinical trial updates and the company's long-term capital requirements.